During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.
More top news
The study by the National Childbirth Trust and National Federation of Women's Institutes found a lack of staff left some women frightened.
Extracts released by 10 Downing Street suggest Mrs May will say the UK will not settle for a "half-in, half-out" policy.
Milder for most of us